Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328625 | 0.95 | F13A1 (0.41) | GPR35F13A1RARBALDH1A1BID | |
| SCHEMBL3334784 | 0.90 | PTPN1 (0.40) | GPR35F13A1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL3333978 | 0.81 | GPR35 (0.43) | GPR35ALDH1A1HCAR3HCAR2NFKB1 | |
| SCHEMBL11261475 | 0.77 | RARB (0.52) | RARBALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL10328631 | 0.77 | ALDH1A1 (0.45) | GPR35GABRA1GABRB2RARBALDH1A1 | |
| SCHEMBL6900481 | 0.75 | MEN1 (0.42) | GPR35MEN1KMT2ATDP1TSHR | |
| SCHEMBL10328605 | 0.74 | MEN1 (0.48) | ALDH1A1HPGDMEN1KMT2ATDP1 | |
| SCHEMBL10328548 | 0.73 | MEN1 (0.50) | ALDH1A1HPGDMEN1KMT2ATDP1 | |
| SCHEMBL9203298 | 0.72 | IDH1 (0.47) | KDM4EL3MBTL1CTRCBCL2L1 | |
| SCHEMBL11634965 | 0.72 | PTGER4 (0.44) | ALDH1A1KDM4EMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748483-B2 | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748483-B2 | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| EP-2120923-B1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI SA (FR) | 2012-07-18 | — | — | EP | disclosed |
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| WO-2008086949-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | PC, PCK1, PDK4 | PDE2A 2659/4885PDE1A 3017/4885PDE1B 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.